T-Cell Receptor-Transduced T Cells: Clinical Experience

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Numerous T-cell epitopes are presented on human tumors, offering potential targets for cancer therapies.
• Current vaccination strategies targeting these epitopes have shown limited efficacy.
• Generating sufficient functional T cells for adoptive immunotherapy in epithelial malignancies remains a challenge.

Purpose of the Study:

• To explore the potential of T-cell receptors (TCRs) targeting shared and unique tumor antigens.
• To develop broadly applicable adoptive cell therapies for common epithelial cancers.

Main Methods:

• Identification and characterization of T-cell epitopes presented on human tumors.
• Engineering of T-cell receptors (TCRs) capable of recognizing these tumor-associated antigens.
• Transduction of autologous T cells with engineered TCRs for adoptive transfer.

Main Results:

• The study highlights a large repertoire of T-cell epitopes across various cancers.
• The engineered TCRs demonstrate the potential to recognize diverse tumor antigens.
• This approach enables the generation of T cells for adoptive immunotherapy.

Conclusions:

• Engineered T-cell receptors offer a promising strategy for developing widely applicable cancer immunotherapies.
• Adoptive transfer of autologous T cells engineered with specific TCRs can target a range of common epithelial cancers.
• This approach holds potential for inducing durable tumor regression.